NCT00664664View on ClinicalTrials.gov

Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia

PHASE2CompletedINTERVENTIONAL
Enrollment

744

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

November 30, 2008

Conditions
Primary Insomnia
Interventions
DRUG

APD125

soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks

DRUG

APD125

soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks

DRUG

Placebo

soft gelatin capsule, daily dosing for up to 3 weeks

Trial Locations (1)

92121

Arena Pharmaceuticals, Inc, San Diego

Sponsors
All Listed Sponsors
lead

Arena Pharmaceuticals

INDUSTRY

NCT00664664 - Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia | Biotech Hunter | Biotech Hunter